公开(公告)号：WO2008073942A2

公开(公告)日：2008-06-19

申请号：PCT/US2007/087090

申请日：2007-12-12

Applicant: ABBOTT LABORATORIES ,  GOPALAKRISHNAN, Murali ,  HONORE, Marie, P. ,  LEE, Chih-hung ,  MALYSZ, John ,  JI, Jianguo ,  LI, Tao ,  SCHRIMPF, Michael, R. ,  SIPPY, Kevin, B. ,  ANDERSON, David, J.

Inventor： GOPALAKRISHNAN, Murali ,  HONORE, Marie, P. ,  LEE, Chih-hung ,  MALYSZ, John ,  JI, Jianguo ,  LI, Tao ,  SCHRIMPF, Michael, R. ,  SIPPY, Kevin, B. ,  ANDERSON, David, J.

IPC: A61K31/4245 ,  A61P25/28 ,  A61K45/06

CPC classification number: A61K31/4439 ,  A61K31/4245 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/444 ,  A61K31/4709 ,  A61K45/06 ,  C07D413/04 ,  C07D413/14 ,  G01N33/944 ,  G01N2333/70571 ,  A61K2300/00

Abstract: The invention relates to a composition comprising a neuronal nicotinic receptor ligand and an α4β2 positive allosteric modulator, a method of using the same, and a related article of manufacture.

Abstract translation: 本发明涉及包含神经元烟碱性受体配体和a4β2正变构调节剂的组合物，其使用方法和相关制品。

公开(公告)号：WO0031290A9

公开(公告)日：2001-03-29

申请号：PCT/US9927582

申请日：1999-11-22

Applicant: PROTEOME SCIENCES INC

Inventor： CAMERON BRUCE M SR ,  ALLEN ROBERT C

IPC: A61K38/46 ,  C12Q1/46 ,  G01N33/52 ,  G01N33/94

CPC classification number: G01N33/523 ,  A61K38/465 ,  C12Q1/46 ,  C12Q2334/30 ,  C12Q2334/70 ,  C12Y301/01007 ,  G01N33/9406 ,  G01N33/944 ,  G01N2800/52 ,  Y10S435/975

Abstract: The present invention provides novel methods and diagnostic kits for the objective measurement of the severity of pain or stress being experienced by a patient with a disorder, diagnosis and treatment for patients suffering from painful disorders, and monitoring the effectiveness of different pain-treatment protocols. Pain-measuring methods comprise collecting a sample from a patient and determining the presence of a pain-associated marker in the sample. Methods for alleviating pain comprise administrating a dose of a therapeutically effective amount of a composition to the patient wherein the dose is determined by the presence of a pain-associated marker in a biological sample obtained from the patient. Compositions for alleviating pain comprise substances that are pain-associated markers or agents that interfere with pain-associated markers, and block or modulate the progression of pain perceived by the patient.

Abstract translation: 本发明提供了用于客观测量患有疼痛病症的患者的病症，诊断和治疗的患者经历的疼痛或压力的严重程度以及监测不同疼痛治疗方案的有效性的新型方法和诊断试剂盒。 疼痛测量方法包括从患者收集样品并确定样品中疼痛相关标志物的存在。 减轻疼痛的方法包括向患者施用治疗有效量的组合物的剂量，其中通过在从患者获得的生物样品中存在疼痛相关标志物来确定剂量。 用于缓解疼痛的组合物包括与疼痛相关的标志物或干扰疼痛相关标志物的试剂以及阻断或调节患者感觉到的疼痛进展的物质。

公开(公告)号：WO99048482A2

公开(公告)日：1999-09-30

申请号：PCT/GB1999/000960

申请日：1999-03-26

IPC: C12N15/09 ,  A61K20060101 ,  A61K31/343 ,  A61K31/352 ,  A61K31/58 ,  A61K31/70 ,  A61K31/704 ,  A61K35/00 ,  A61K36/18 ,  A61K36/896 ,  A61P9/00 ,  A61P21/04 ,  A61P25/16 ,  A61P25/18 ,  A61P25/28 ,  A61P43/00 ,  C07D493/10 ,  C07J71/00 ,  C12Q1/68 ,  G01N33/94 ,  A61K31/00

CPC classification number: A61K31/704 ,  A61K31/58 ,  A61K31/7048 ,  A61K36/88 ,  A61K36/896 ,  A61K36/8964 ,  A61K36/8965 ,  A61K36/90 ,  G01N33/944

Abstract: The invention discloses the use of a smilagenin and anzurogenin-D in the treatment of cognitive disfunction and similar conditions. Methods of treatment, and pharmaceutical compositions are also disclosed.

Abstract translation: 本发明公开了用于治疗认知功能障碍和类似病症的杀螟昔宁和嘌呤嘌呤D的用途。 还公开了治疗方法和药物组合物。

公开(公告)号：WO1997017431A1

公开(公告)日：1997-05-15

申请号：PCT/GB1996002725

申请日：1996-11-07

Applicant: ISIS INNOVATION LIMITED ,  BEESON, David, Murray, Wendaver ,  VINCENT, Angela

Inventor： ISIS INNOVATION LIMITED

IPC: C12N05/10

CPC classification number: C07K14/70571 ,  C07K14/4713 ,  G01N33/564 ,  G01N33/944 ,  G01N2500/00

Abstract: Cells of the clones CN21 and DB30S and DB40 express a form of an acetylcholine receptor (AChR) containing an adult epsilon subunit. The AChR is useful in an assay for AChR antibodies which is diagnostic of myasthenia gravis.

Abstract translation: 克隆CN21和DB30S和DB40的细胞表达含有成年ε亚基的乙酰胆碱受体（AChR）的形式。 AChR可用于重症肌无力诊断的AChR抗体检测。

公开(公告)号：WO1995013299A1

公开(公告)日：1995-05-18

申请号：PCT/US1994012859

申请日：1994-11-08

Applicant: THE SALK INSTITUTE BIOTECHNOLOGY/INDUSTRIAL ASSOCIATES, INC. ,  ELLIOTT, Kathryn, J. ,  ELLIS, Steven, B. ,  HARPOLD, Michael, M.

Inventor： THE SALK INSTITUTE BIOTECHNOLOGY/INDUSTRIAL ASSOCIATES, INC.

IPC: C07K14/705

CPC classification number: C07K14/70571 ,  G01N33/944 ,  G01N2500/10

Abstract: DNA encoding human neuronal nicotinic acetylcholine receptor alpha 2 subunits, mammalian and amphibian cells containing said DNA, and methods for producing such subunits are provided. In addition, combinations of subunits (i.e., alpha 2, plus alpha 1, alpha 3, alpha 4, and/or alpha 7 subunits in combination with beta 2, beta 3 and/or beta 4 subunits) are provided.

Abstract translation: 提供编码人神经元烟碱乙酰胆碱受体α2亚基的DNA，含有所述DNA的哺乳动物和两栖动物细胞，以及用于制备这些亚基的方法。 此外，还提供了亚基（即α2，加上α1，α3，α4和/或α7亚基与β2，β3和/或β4亚基组合）的组合。

公开(公告)号：WO2007084535A2

公开(公告)日：2007-07-26

申请号：PCT/US2007/001193

申请日：2007-01-17

Applicant: ABBOTT LABORATORIES ,  VERLINDEN, Maria-Helena ,  MEYER, Michael, D. ,  DECKER, Michael, W. ,  SULLIVAN, James, P. ,  BUNNELLE, William, H.

Inventor： VERLINDEN, Maria-Helena ,  MEYER, Michael, D. ,  DECKER, Michael, W. ,  SULLIVAN, James, P. ,  BUNNELLE, William, H.

IPC: A61K31/40 ,  A61K31/435 ,  A61P25/28

CPC classification number: A61K31/40 ,  A61K31/435 ,  A61K31/4439 ,  G01N33/944 ,  G01N2500/00

Abstract: The invention relates to neuronal nicotinic receptor ligands, methods of identifying such ligands for neuronal nicotinic receptor modulation, particularly such ligands demonstrating beneficial side effect tolerability, and methods of using such neuronal nicotinic receptor ligands to provide pharmaceutical compositions and products.

Abstract translation: 本发明涉及神经元烟碱受体配体，鉴定用于神经元烟碱受体调节的此类配体的方法，特别是证实有益的副作用耐受性的此类配体，以及使用此类神经元烟碱受体配体来提供药物组合物的方法 和产品。

公开(公告)号：WO2007057428A1

公开(公告)日：2007-05-24

申请号：PCT/EP2006/068553

申请日：2006-11-16

Applicant: EPFL - ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE ,  GRANDL, Jörg ,  HOVIUS, Rudolf ,  VOGEL, Horst ,  BERTRAND, Daniel ,  SAKR, Elias ,  KOTZYBA-HIBERT, Florence ,  GOELDNER, Maurice

Inventor： GRANDL, Jörg ,  HOVIUS, Rudolf ,  VOGEL, Horst ,  BERTRAND, Daniel ,  SAKR, Elias ,  KOTZYBA-HIBERT, Florence ,  GOELDNER, Maurice

IPC: G01N33/58

CPC classification number: G01N33/582 ,  G01N33/6872 ,  G01N33/944

Abstract: The present invention is directed to conjugates of chromophores with agonistic ligands directed to ligand-gated ion channels (LGICs) of the Cys loop-family. The conjugated ligands bind specifically and with high affinity to their cognate receptors, allowing to measure directly the binding of these ligands to the receptors, to quantify the affinity of unlabelled compounds for the receptor, to detect receptor activation, and to inspect and image presence of and behaviour of said receptors in living or fixed cells or tissues, either in situ or ex vivo, or on (semi-) purified receptor preparations.

Abstract translation: 本发明涉及发色团与针对Cys环族的配体门控离子通道（LGIC）的激动配体的缀合物。 共轭配体与其同源受体具有特异性结合并具有高亲和力，可直接测量这些配体与受体的结合，定量未标记化合物对受体的亲和力，检测受体活化，以及检测和图像存在 和所述受体在活的或固定的细胞或组织中的原位或离体或（半）纯化的受体制剂的行为。

公开(公告)号：WO2006024483A1

公开(公告)日：2006-03-09

申请号：PCT/EP2005/009314

申请日：2005-08-30

Applicant: BAYER HEALTHCARE AG ,  GOLZ, Stefan ,  BRÜGGEMEIER, Ulf ,  GEERTS, Andreas

Inventor： GOLZ, Stefan ,  BRÜGGEMEIER, Ulf ,  GEERTS, Andreas

IPC: G01N33/68 ,  C12Q1/68 ,  C07K14/705

CPC classification number: G01N33/566 ,  G01N33/944 ,  G01N2333/726 ,  G01N2500/04

Abstract: The invention provides a human ACM3 which is associated with the cardiovascular diseases, cancer, dermatological diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, hematological diseases, muscle skeleton diseases, neurological diseases, urological diseases, respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, cancer, dermatological diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, hematological diseases, muscle skeleton diseases, neurological diseases, urological diseases, respiratory diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of ACM3 as well as pharmaceutical compositions comprising such compounds.

Abstract translation: 本发明提供了与心血管疾病，癌症，皮肤病，内分泌疾病，代谢疾病，炎症，肠胃病，血液病，肌肉骨骼疾病，神经系统疾病，泌尿科疾病，呼吸系统疾病有关的人ACM3。 本发明还提供了用于鉴定可用于治疗或预防心血管疾病，癌症，皮肤病，内分泌疾病，代谢疾病，炎症，胃肠病，血液疾病，肌肉骨骼疾病，神经系统疾病，泌尿系统疾病，呼吸系统疾病 疾病。 本发明还涉及结合和/或活化或抑制ACM3的活性的化合物以及包含这些化合物的药物组合物。

公开(公告)号：WO2005074641A2

公开(公告)日：2005-08-18

申请号：PCT/US2005003474

申请日：2005-01-28

Applicant: UNIV FLORIDA ,  PAPKE ROGER L ,  PLACZEK ANDON

Inventor： PAPKE ROGER L ,  PLACZEK ANDON

IPC: C12Q1/68 ,  G01N33/94

CPC classification number: G01N33/944 ,  C12Q1/6883 ,  C12Q2600/156 ,  G01N2500/10

Abstract: The present invention relates to a variant of the nicotinic acetylcholine receptor (nAChR) alpha7 subunit having a substitution within its second transmembrane (TM2) domain. Specifically, the sixth amino acid position within the TM2 domain has the point mutation T-> S, such that threonine-244 becomes serine-244. Advantageously, the alpha7 variant of the present invention retains the essential drug sensitivities of the wild-type alpha7 receptor, but does not exhibit the response-limiting form of fast desensitization. Therefore, the alpha7 variant is a "gain of function" mutant that is particularly useful for testing new pharmacological agents. The present invention includes the T6'S variant TM2 domain, T6'S variant alpha7 subunit, and T6'S variant nACh receptor polypeptides, polynucleotides encoding these polypeptides, recombinant hosts expressing these polynucleotides, and assays utilizing the T6'S variant TM2 domain, T6'S variant alpha7 subunit, and/or T6'S variant nACh receptor.

Abstract translation: 本发明涉及在其第二跨膜（TM2）结构域内具有置换的烟碱乙酰胆碱受体（nAChR）α7亚基的变体。 具体来说，TM2结构域内的第六个氨基酸位点具有突变点T> S，使得苏氨酸-244变为丝氨酸-244。 有利地，本发明的α7变体保留野生型α7受体的基本药物敏感性，但不表现出快速脱敏作用的响应限制形式。 因此，alpha7变体是“功能增益”突变体，特别适用于测试新的药理学试剂。 本发明包括T6'S变体TM2结构域，T6'S变体α7亚基和T6'S变体nACh受体多肽，编码这些多肽的多核苷酸，表达这些多核苷酸的重组宿主，以及利用T6'S变体TM2结构域，T6'S变体α7亚基和/或 T6'S变体nACh受体。

公开(公告)号：WO2004091646A2

公开(公告)日：2004-10-28

申请号：PCT/IB2004/001716

申请日：2004-04-16

Applicant: UNIVERSITE DE LAUSANNE ,  UNIVERSITE DE GENEVE ,  CHIMIENTI, Fabrice ,  HOGG, Ronald ,  HUBER, Marcel ,  BERTRAND, Daniel ,  HOHL, Daniel

Inventor： CHIMIENTI, Fabrice ,  HOGG, Ronald ,  HUBER, Marcel ,  BERTRAND, Daniel ,  HOHL, Daniel

IPC: A61K38/00

CPC classification number: G01N33/6896 ,  A61K38/177 ,  G01N33/6881 ,  G01N33/944 ,  G01N2333/4719 ,  G01N2500/00

Abstract: Disclosed herein are compositions and methods for the treatment or prevention of neurological disorders. Also disclosed are compositions and methods for the treatment or prevention of skin pathologies. The invention further discloses compositions and methods for the modulation of acetylcholine receptor activity. Antibodies generated against SLURP-1 and related proteins are also included.

Abstract translation: 本文公开了用于治疗或预防神经障碍的组合物和方法。 还公开了用于治疗或预防皮肤病变的组合物和方法。 本发明进一步公开了用于调节乙酰胆碱受体活性的组合物和方法。 还包括针对SLURP-1和相关蛋白产生的抗体。